Published in AIDS Weekly, February 27th, 2006
According to recently published research from Sweden, "Leukemia inhibitor factor (LIF) is thought to play a substantial role in protecting CD4 T cells in lymphoid tissues (LT) from infection by HIV-1.
"To investigate whether primary HIV-1 infected subjects with sustained virological control (<1000 HIV-1 RNA copies/mL plasma) postcessation antiretroviral therapy (ART) had a higher initial LIF response during primary HIV-1 infection (PHI) as compared with those individuals who did not achieve a similar control (>9000 HIV-1 RNA...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.